ABCLON INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17,040 KRW | -4.27% |
|
-12.84% | +14.98% |
ETFs positioned on AbClon Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 7 M€ | +0.11% | - |
AbClon Inc. is a Korea-based company principally engaged in the development, manufacture and distribution of antibody drug. The Company developed a bio synergy antibody, a therapeutic antibody for a new mechanism that is different from conventional therapeutic agents, and is based on the YPLUS and AffiMab platforms. The company's products include AC101, AC103, AC104, AC106, AC203, AM201, AM101, AM102 and AM103. The Company distributes its products within domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
08/08/2024
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +14.98% | 212M | |
| -2.29% | 89.87B | |
| -3.95% | 37.57B | |
| +63.05% | 26.47B | |
| -22.14% | 14.25B | |
| -7.96% | 12.99B | |
| -9.33% | 11.93B | |
| -46.33% | 10.84B | |
| +5.77% | 9.11B | |
| -17.66% | 7.32B |
- Stock Market
- Equities
- A174900 Stock
- Funds and ETFs AbClon Inc.
